Palmar-Plantar Erythrodysesthesia

Presented by: Elizabeth Lynn, BSN, RN, MSN Candidate
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 29 de mayo de 2015

Continuing Education Information

This continuing education activity is designed to enable nurses and nurse practitioners in clinical practice to understand the pathophysiology of palmar-plantar erythrodysesthia, identify symptoms and describe the management of this complication of chemotherapy.

This activity has been approved for 1.0 contact hour by the Hospital of the University of Pennsylvania, Department of Nursing Development and Education, an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

To receive continuing education credits for this activity:

  • Read the article below.
  • Click on the link at the end to go to the posttest, fill in your contact information and complete the test.
  • If you do not achieve a passing score, you will return to the test and be able to retake the posttest.
  • If you achieve a score of 80% or higher, you can proceed to the evaluation form.
  • Once you submit the evaluation, the CE certificate will pop up. Please print this for your records. You will also receive a copy by email.

The presenters and planning committee report no conflicts of interest.

This activity expires June 1, 2015.

The educational objectives of this activity are:

  • Identify the clinical significance of PPE in people with cancer.
  • Describe the pathophysiology and clinical presentation of PPE in people with cancer.
  • List current evidence-based pharmacologic and non-pharmacologic management strategies.

Overview and Clinical Significance

Palmar-Plantar Erythrodysesthesia (PPE), also known as Palmar-Plantar Erythema, Acral Erythema, Hand-Foot Syndrome (HFS), and Burgdorf's Reaction, is a common adverse reaction to many cytotoxic chemotherapies and multikinase inhibitors (MKI) (Degen et al., 2010). PPE is characterized by symmetric palmar and/or plantar erythema and desquamation with pain, parasthesia (abnormal sensation), and temperature intolerance (particularly to heat) (Bos, Nijsten, de Jonge, & Hamberg, 2012). PPE is considered a common adverse effect in many frequently used cancer therapies, including Pegylated Liposomal Doxorubicin, 5-FU, capecitabine, sorafenib, and sunitinib (Degen et al., 2010). PPE is a less common adverse effect in many other therapies, including Methotrexate, Cisplatin, and Paclitaxel. Table 1 demonstrates the breadth of therapeutic agents that are associated with PPE.

Table 1: Cancer Treatments associated with Palmar-Plantar Erythrodysesthesia (Degen et al., 2010)

Common Adverse Effect

Less Common Adverse Effect

  • Doxorubicin
  • Pegylated Liposomal Doxorubicin
  • Docetaxel
  • Cytarabine
  • Fluorouracil
  • Capecitabine
  • Sorafenib
  • Sunitinib
  • Paclitaxel
  • Hydroxyurea
  • Methotrexate
  • 6-Mercapturpurin
  • Cyclophosphamide
  • Cisplatin
  • Daunorubicin
  • Etoposide
  • Vinorelbine
  • Irinotecan
  • Epirubicin

While PPE is not a life threatening condition, it can have a serious effect on a patient's quality of life, requiring dose reduction and/or interruption of treatment, and presents a risk that the patient will become noncompliant with their treatment plan (Anderson et al., 2009). Patients receiving capecitabine experience a 10-17% incidence rate of grade 3 PPE, and PPE is considered the most common dose-limiting adverse reaction when treating with capecitabine (Azuma et al., 2012). In patients treated with Multikinase Inhibitors (MKIs), the incidence of PPE results in dose reductions in 40-44% of patients, brief treatment interruptions for 29-30% of patients, and discontinuation of treatment in 17-19% of patients (Choi, 2011).

The incidence and severity of PPE is both dose and schedule dependent. Schedule dependence is demonstrated in the use of 5-FU, where continuous infusion is associated with higher incidence of PPE (median 35%) than bolus (median 6.2%). Capecitabine has an even higher incidence rate of PPE (median 53.5%) (Yen-Revollo, 2008). Dose dependence is demonstrated in the incidence and severity of PPE for patients receiving Sorafenib, with infrequent incidence of PPE occurring in doses under 300 mg BID, and increased incidence and severity for doses 300-600 mg BID, and a dose limiting toxicity at 600 mg BID.

The precise etiology of PPE is unclear. The clinical and microscopic cellular changes seen in PPE are similar to other types of toxic damage to the skin, including reaction that is dose dependent, increased incidence with prolonged exposure, and increased frequency and severity when multiple substances which cause PPE are combined (Degen et al., 2010). Yet without understanding the underlying mechanism that is causing the damage, treatment has been generally limited to attempting to prevent injury and treating symptoms. It is therefore critical when caring for a patient at risk for PPE to educate the patient about the condition and its symptoms, protective measures the patient can use to reduce the occurrence of PPE, and methods for treating the condition should it occur. And, while the mechanism underlying the skin damage associated with PPE is not fully understood, the relationship between the incidence and severity of PPE and the efficacy of cancer treatment has been positively correlated (Azuma et al., 2012). Research has demonstrated a positive relationship between capecitabine associated PPE and efficacy of treatment of colorectal cancer in terms of disease control rate and progression free survival (Azuma et al., 2012). Therefore management of PPE symptoms and progression to enable patients to continue with their treatment regimen uninterrupted provides the best hope for positive treatment outcomes.


While the exact cause of Palmar-Plantar Erythrodysesthesia is unknown, there are a number of theories as to the cause, from excretion of substances directly causing damage, to vascular micro trauma causing leakage of substances into tissue resulting in damage. There has also been research focused on the variation in incidence of PPE within populations, and the potential for pharmacogenetic involvement in the incidence and level of severity.

  • A leading theory as to the cause of PPE relates to the principle that mechanical stresses to capillary beds in the hands and feet cause leakage of the toxic agent into the surrounding tissue (Degen et al., 2010). In the case of PPE associated with MKI, the anti-angiogenic effects of MKI would also impair the ability of capillaries to repair, thereby resulting in higher concentration of the toxic agent (Degen et al., 2010). This theory is supported by clinical evidence that increased activities involving hands and feet leads to increased severity of PPE (Choi, 2011). It is also supported by two case reports of patients with hemiparesis (weakness on one side of body) who received capecitabine and experienced rare unilateral PPE on the functional sides of their bodies (Almeida da Cruz, Hoff, Ferrari, & Riechelmann, 2012).
  • An additional theory is that PPE is the result of secretion of the agent from sweat glands, leading to local skin toxicity. The increased number of eccrine sweat glands found in the extremities would explain the concentration of symptoms to the palms and soles. This theory has been supported by the observation that certain agents (taxanes, liposome doxorubicin) can affect areas other than the hands and feet where there are an increased number of sweat glands (Degen et al., 2010). However, research into this theory has found mixed results. In research involving patients receiving sorafenib, it was found that there were undetectable levels of sorafenib in the sweat samples from the palms and soles of patients with PPE, invalidating this theory as it relates to sorafenib (Jain et al., 2010).
  • Another theory specific to capecitabine associated PPE is concerned with damage to skin from active metabolites. Capecitabine is metabolized to 5-FU by thymidine phosphorylase (TP), which is found in higher concentration in tumors and in the skin of the hands and soles of the feet. The concentration of TP in the hands and feet could lead to higher concentrations of active metabolites in these areas, and greater damage to the skin.
  • An important area of research is considering the large variation in incidence of PPE, and certain genetic polymorphisms associated with enzymes for capecitabine conversion. Research has identified a genetic polymorphism that involves the deletion of a specific nucleotide sequence. The nucleotide variation results in increased gene expression and increased production of an enzyme involved in capecitabine conversion, which in turn is significantly associated with increased risk of PPE (Caronia et al., 2011).
  • Another area of research involves the theory that certain polymorphisms associated with ethnic differences can lead to differences in PPE incidence and severity. Research into the higher incidence of PPE in Asian patients following administration of sorafenib has identified polymorphisms in the TNF-a, VEGF, and UTGIA9 genes that are associated with increased incidence of severe PPE (Lee et al., 2013). Understanding differences in incidence and severity among ethnic populations will aid providers in fine-tuning education and support for high risk patients.

Clinical Presentation

Table 2 presents the National Cancer Institute Common Terminology Criteria for Adverse Events (V4.02) for Palmar-Plantar Erythrodysesthesia regardless or precipitating agent.

Table 2: Plantar Palmar Erythrodysesthesia
National Cancer Institute (NCI-CTCAE Version 4.02)





Minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis), without pain

Skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting instrumental ADL

Severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self care ADL

PPE associated with chemotherapy presents slightly differently than PPE associated with MKIs. Because of the increased use of combination therapies, it is important for clinicians to be able to differentiate the features of chemotherapy associated PPE and MKI associated PPE in order to adjust the dose of specific agent causing the PPE and to maintain dose intensity of the remaining agent (Gomez & Lacouture, 2011).

PPE associated with chemotherapy begins with dysesthesia (unpleasant, abnormal sensation), followed within a few days by burning pain and sharply outlined erythema with swelling that may develop into blisters (Degen et al., 2010). Generally PPE begins early in therapy, although it can occur one or more months after beginning treatment (Degen et al., 2010). There can be desquamation of the stratum corneum layer of skin, followed by ulceration or erosions (Degen et al., 2010). The lesions are found mainly on the palms of the hands and soles of the feet, with plantar symptoms more severe. In severe cases patients can experience the same symptoms on the dorsum of the hands and feet, intertriginous areas, and areas covered by tight fitting clothing (Degen et al., 2010). PPE associated with chemotherapy can occur 1-21 days after initiating therapy, and up to several months later with continued low-dose therapies (Choi, 2011). Permanent damage is rare in PPE, and significant improvement is experienced within weeks of discontinuing treatment (Degen et al., 2010).

The early symptoms of PPE associated with the MKIs sorafenib and sunitinib are the same as chemotherapy, with dysesthesia, burning pain, and erythema with swelling (Degen et al., 2010). Patients receiving sorafenib have a median onset of symptoms of 18.4 days (range 3-56 days), and sunitinib has a later onset with a median of 32.4 days (range 5-82 days) (Degen et al., 2010). Unlike the symptoms associated with chemotherapy, PPE associated with MKIs does not affect the dorsum of the hands and feet or intertriginous areas (Degen et al., 2010). The symptoms are most pronounced on the pressure points of the palms and soles of feet, even affecting the margins of the feet and skin between the toes and fingers (Degen et al., 2010). PPE associated with MKIs can also affect areas of the body under mechanical stress, including sites of amputation, fingertips, and on skin overlying joints (Almeida da Cruz et al., 2012). It can also cause callus-like thickening of the stratum corneum, formation of large, tense blisters, and can worsen quickly within days (Gomez & Lacouture, 2011). Table 3 summarizes the differentiating symptoms associated with specific agents.

Table 3: Differentiation of PPE associated with Chemotherapy and MKIs
(Gomez & Lacouture, 2011)

Drug Class


Anthracyclines/ Antimetabolites


Lesion Type

Erythematous Maculopapules

Edema, erythema, and fissuring

Blisters with erythematous halo, followed by hyperkeratosis

Schedule Specific?




Location In Hands


Ventral, diffuse Palmar

Ventral, Digit Tips, Over IP Joints, Thenar And Hypothenar

Location In Feet

Dorsal, Achilles tendon, malleoli

Ventral, diffuse on soles

Ventral, heels and forefoot

Nail Changes



Subungual Hemorrhages

The incidence and severity of PPE is based in part on the type of agent, schedule, and dose. Appendix 1 lists common agents, dosing regimens and incidence of PPE. Combination therapies that involve two PPE causing agents have the highest incidence of PPE as well as the highest occurrence of severe (grade 3) PPE. Severe cases of PPE, regardless of the agent(s) involved, can result in ulcerative dermatitis or skin thickening with severe pain that has a significant impact on a patient's ability to walk, manipulate objects with their hands, and to perform self care (Choi, 2011).

Differential Diagnosis

There are a number of skin conditions that affect the palmar and/or plantar surfaces. The following is a list of common differential diagnosis and distinguishing factors.

  • Acral Erythema associated with acute Graft-versus-Host Disease. Will usually occur within 4-7 days following allogeneic bone marrow transplant, but can be delayed as long as 100 days. Erythema will present on dorsal aspects of fingers and within the periungual skin. Patient will experience pruritis and tenderness of the palms and soles (as compared to severe pain and swelling of PPS). Can also present with nausea, vomiting, diarrhea, and severe rise in serum bilirubin levels. Can occur concurrently with PPE (Abeloff, Armitage, Niederhuber, Kastan, & McKenna, 2008)
  • Acral erythema occurring in severe liver disease – This condition is not generally accompanied with pain, blistering, or desquamation of skin. Patient will experience severe liver serum abnormalities. (Abeloff et al., 2008)
  • Telangiectasia associated with Lupus Erythematosus â€" in addition to erythema of palm and fingers, telangiectasia will be visible with ophthalmoscope in affected areas, with some disorganization of capillary pattern. Avascular areas are rare. Only associated with Lupus patients. (Habif, 2010)
  • Neutrophilic eccrine hidradenitis â€" presents as localized necrosis of eccrine glands, tender erythematous to purpuric macules, papules, nodules, plaques on any body area. Can occur during active administration of cytotoxic agent (within 2-3 days), fever often accompanies onset of lesions. Condition usually resolves within 7-21 days despite continued chemotherapy administration. (Abeloff et al., 2008)
  • Idiopathic Palmoplantar Hidradenitis â€" This condition presents primarily in otherwise healthy children with tender erythematous macules and nodules, localized and unilaterally or bilaterally on palms and/or soles, lasting 1-4 weeks. (Elser-Brauer & Rothman, 2007)
  • Fingertip eczema - This condition presents as a dry, chronic form of eczema on the palmar surface of one or more fingertips. It may be result of an allergic reaction, and can last months to years. The affected skin is initially moist, then dry and cracked and scaly. The condition does not extend past the distal interphalangeal joint (Habif, 2010).
  • Hyperkeratotic eczema – A very thick, chronic form of eczema affecting almost exclusively men, which occurs on the palms and occasionally soles. It manifests as one to several plaques of yellow-brown, dense scale. The dense scale, unlike callus, is moist below surface and not easily reduced with a blade. This condition results from allergy, excoriation, irritation, or unknown etiology. It is often a chronic condition lasting for years. Differs from PPE as it is not painful and lacks erythema. (Habif, 2010)
  • Recurrent focal palmar peeling – aka keratolysis exfoliativa, is a common, chronic, asymptomatic, non-inflammatory, bilateral peeling of palms of hands and occasionally soles of feet of unknown etiology. Usually occurs in summer and is associated with sweaty palms. Usually resolves without treatment in 1-3 weeks. Unlike PPE, there is no inflammation or pain. (Habif, 2010)
  • Pompholyx (dyshidrosis) – This is a distinctive reaction of unknown etiology manifesting as symmetric vesicular hand and foot dermatitis. Moderate to severe itching precedes appearance of vesicles. Palms may be red and wet with perspiration. The vesicles slowly resolve in 3-4 weeks, replaced with rings of scale. Chronic eczematous changes are observed, including erythema, scaling, and eventually licenification. Pain rather than itching chief complaint. (Habif, 2010)

Management Strategy

The management strategy for PPE consists of measures to prevent occurrence of the condition, as well as interventions to treat an occurrence. Very little of the management techniques are evidence based, but are rather based on experiences in clinical practice and/or based on one or more of the theories regarding the condition's pathophysiology.


Management of PPE starts with patient education and communication. It is critical that the patient be engaged prior to treatment in a discussion regarding the early signs and symptoms of PPE (Gomez & Lacouture, 2011), and that there are ongoing reassessment of PPE symptoms and the impact on the patient using a tested quality of life measure (Dermatology Quality of Life / DLQI, Skindex-16, or PPE specific HFS-14) (Sibaud et al., 2011). Patient education should include prophylactic measures which have been shown in clinical practice to reduce the incidence and/or severity of PPE, including:

  • Avoiding trauma to hands and feet (e.g., high impact sports or activities, heavy lifting/carrying/long walks, repetitive use of tools);
  • Avoiding exposure of hands and feet to hot water;
  • Bathing in lukewarm water, using mild soaps such as Aveeno® or Cetaphil®, and pat skin dry (do not rub);
  • Using topical moisturizers;
  • Avoiding constrictive footwear and excessive friction to skin (constricting clothing, gloves);
  • Wearing thick cotton gloves and socks, and shoes with padded insoles (avoid going barefoot);
  • Cooling hands and feet 3-4 times a day, avoiding excessive warmth;
  • Immersion of hands/feet in cold water during short duration infusion of chemotherapy.

(Choi, 2011; Degen et al., 2010; Almeida da Cruz et al., 2012; Yen-Revollo, 2008; Gomez & Lacouture, 2011)

Prior to initiating treatment, a comprehensive skin exam of the entire body should be conducted to identify predisposing factors for PPE (hyperkeratosis, eczema, fungal disease, or misalignment) (Gomez & Lacouture, 2011). If indicated, a pedicure by a podiatrist and/or an evaluation by orthotist should be ordered (Gomez & Lacouture, 2011). To the extent possible, pre-existing skin conditions and risk factors should be addressed prior to initiating treatment.

Research has identified a limited number of pharmacological treatments that have been used successfully to reduce the frequency and severity of PPE under specific circumstances. A single clinical study found that inhibitors of dihydropyrimidine dehydrogenase (DPYD), such as Gimeracil, reduced the incidence of PPE in patients receiving fluoropyrimidines (5-FU and capecitabine) (Yen-Revollo, 2008). The mechanism of action of DPYD inhibitors in reducing the incidence of PPE is supported by research by Almeida da Cruz et al. (2012), which found that individuals with DPYD deficiency have decreased incidence in PPE. Other research has found the incidence and severity of PPE in patients receiving capecitabine alone or capecitabine + oxaliplatin is reduced with the use of cyclooxygenase 2 inhibitors such as Celecoxib (Degen et al., 2010; Zhang, 2012). The researchers have theorized that Celecoxib impairs circulation to the hands and feet, thereby reducing exposure to the cytotoxic agent. A similar mechanism of action has been proposed in retrospective studies of the use of nicotine patches during and after administration of capecitabine. A retrospective study has found nicotine patches to reduce the incidence and severity of PPE in patients receiving capecitabine, and the efficacy of nicotine patches is currently being further studied by the National Cancer Institute in a clinical trial (Degan, 2010; Almeida da Cruz et al., 2012).


A number of treatments have been found to relieve the symptoms and limit the severity of PPE. In cases of severe, debilitating grade 3 PPE, discontinuing treatment until the patient experiences improvement in symptoms is effective, and often treatment can be resumed with dose reduction without recurrence of severe PPE (Almeida da Cruz et al., 2012). In addition to the aforementioned treatments recommended to prevent the occurrence of PPE, topical treatment has been found to be beneficial for treating PPE. The treatment guidelines are dependent on the manifestation of the PPE and the cancer treatment agent:

Treatment by Manifestation
  • For tender, hyperkeratotic plaques, use topical agents that inhibit keratinocyte proliferation, including urea 20-40% cream, 5-10% salicylic acid 6%, tazarotene 0.1% cream, and fluorouracil 5% twice daily to affected areas only (Choi, 2011; Degen et al., 2010; Gomez & Lacouture, 2011)
  • For inflammation and painful erythema, use topical steroids twice daily to affected areas only, e.g., mometasone, clobetasol 0.05% fluocinonide 0.05% (Degen et al., 2010)
  • For blisters and erosions, use topical antibiotics (Gomez & Lacouture, 2011)
  • For Grade 1 symptoms: moisturizing creams, e.g., Udderly Smooth®, Aquaphor®, Eucerin®, Bag Balm®, Am-Lactin®, Lac-Hydrin® (Gomez & Lacouture, 2011)
  • For pain management, treat with systemic medicine (e.g., NSAIDS, g-aminobutyric acid agonists, narcotics) after assessing risk of bleeding and kidney function (Gomez & Lacouture, 2011)
Treatment by Cancer Treatment Agent
  • Doxorubicin – topical DMSO (a radical interceptor, used successfully to treat doxorubicin extravasation) (Degen et al., 2010; Gomez & Lacouture, 2011)
  • 5-FU and capecitabine – topical uridine (a purine competitor) (Degen et al., 2010)

Research has been conducted on effectiveness of pharmacological treatments in treating PPE. For example, there has been considerable research as to the efficacy of pyridoxine (Vitamin B6) to prevent or treat PPE, with mixed results. While the most recent randomized trials have found pyridoxine (200 mg/day) to have no effect on PPE outcomes for patients receiving capecitabine or liposomal doxorubicin (Almeida da Cruz, 2012; von Grueniger et al., 2010; Wolf et al., 2010), there have been case studies that have found pyridoxine (150-300 mg/day) has been successful in limiting the severity of PPE in patients receiving docetaxel and 5-FU (Degen et al., 2010). Non-pharmacological treatments have also been investigated. An analysis of case studies by Bos et al. (2012) found that topical UV-A controlled the severity of PPE in patients receiving TKI therapy. Researchers have theorized that UV-A might have an anti-inflammatory effect, reducing chemokines involved in the neuropathic pain process.


Palmar-Plantar erythrodysesthesia (PPE) is a common adverse affect from many chemotherapies and multikinase inhibitors, including capecitabine, 5-FU, docetaxel, doxorubicin, sorafenib and sunitinib. While not a life threatening reaction, PPE can severely affect the quality of life for the patient, inhibiting self-care and often resulting in non-adherence to the treatment plan. The etiology of PPE is unknown, although it is widely understood to be a toxic reaction to the therapeutic agent, and there are reasonable theories as to the underlying process. Prevention and treatment of PPE is primarily based on clinical experience, with little research-based evidence. However, there are easily implemented activity modifications and preventative measures that patients can use to reduce the incidence and severity of PPE. The primary tool for preventing PPE is patient education about PPE symptoms, preventative measures, and treatment, and ongoing surveillance with timely treatment.


Abeloff, M., Armitage, J., Niederhuber, J., Kastan, M., & McKenna, W. (2008). Abeloff's Clinical Oncology. Philadelphia, PA: Churchill Livingstone.

Almeida da Cruz, L., Hoff, P., Ferrari, C., & Riechelmann, R. (2012). Unilateral Hand-Foot Syndrome: Does It Take Sides? Case Report and Literature Review. Clinical Colorectal Cancer , 11 (1), 82-84. doi: 10.1016/j.clcc.2011.05.004

Anderson, R., Jatoi, A., Robert, C., Wood, L., Keating, K., & Lacouture, M. (2009). Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by Multikinase Inhibitors (MKIs). The Oncologist , 14, 291-302. doi: 10.1634/theoncologist.2008-0237

Azuma, Y., Hata, K., Sai, K., Udagawa, R., Hirakawa, A., Tohkin, M., Ryusima, Y., Makino, Y., Yokete, N., Morikawa, N., Fujiwara, Y., Saito, Y., & Yamamoto, H. (2012). Significant Association Between Hand-Foot Syndrome and Efficacy of Capecitabine in Patients with Metastatic Breast Cancer. Biological & Pharmaceutical Bulletin , 35 (5), 717-724.

Bos, W., Nijsten, T., de Jonge, M., & Hamberg, A. P. (2012). Topical Psoralen Plus UV-A Theraphy for Tyrosine Kinase Inhibitor-Induced Hand-Foot Syndrome. Archives of Dermatology , 148 (4), 546-547.

Caronia, D., Martin, M., Sastre, J., de la Torre, J., Garcia-Saenz, J., Alonso, M., Moreno, L., Pita, G., Diaz-Rubio, E., Benitez, J., & Gonzalez-Neira, A. (2011). A Polymorphism in the Cytidine Deaminase Promoer Predicts Severe Capecitabine-Induced Hand-Foot Syndrome. Clinical Cancer Research , 17 (7), 2006-2013. doi:10.1158/1078-0432.CCR-10-1741

Choi, J. (2011). Chemotheraphy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology , 29, 587-601. doi:10.1016/j.clindermatol.2011.08.032

Degen, A., Alter, M., Schenck, F., Satzger, I., Volker, B., Kapp, A., & Gutzmer, R. (2010). The hand-foot-syndrome associated with medical tumor therapy - classification and mangement. Journal of the German Society of Dermatology , 8, 652-661. DOI: 10.1111/j.1610-0387.2010.07449.x

Elser-Brauer, L., Rothman, I. (2007). Tender nodules on the palms and soles: palmoplantar eccrine hidradenitis. Archives of Dermatology , 143 (9), 1201-1206.

Gomez, P., & Lacouture, M. (2011). Clinical Presentation and Management of Hand-Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Exerience in Breast Cancer. The Oncologist , 16, 1508-1519. doi: 10.1634/theoncologist.2011-0115

Habif, T. (2010). Clinical Dermatology (5th ed.). Philadelphia, PA: Elsevier.

Jain, L., Gardner, E., Figg, W., Chernick, M., & Kong, H. (2010). Lack of association between excretion of sorafenib in sweat and hand-foot reaction. Pharmacotherapy , 30 (1), 52-56. doi:10.1592/phco.30.1.52.

Lee, J., Chung, Y., Kim, J., Shim, J., Lee, D., Lee, H., Shin, E., Yoon, J., Kim, B., Bae, S., Koh, K., & Park, N. (2013). Genetic Predisposition of Hand-Foot Skin Reaction after Sorafenib Theraphy in Patients with Hepatocellular Carcinoma. Cancer , 119, 136-142. DOI: 10.1002/cncr.27705

Sibaud, V., Dalenc, F., Chevreau, C., Roche, H., DeLord, J., Mourey, L., Lacaze, J. Rahhali, N., & Taieb, C. (2011). HFS-14, A Specific Quality of Life Scale Developed for Patients Suffering form Hand-Foot Syndrome. The Oncologist , 16, 1469-1478. doi: 10.1634/theoncologist.2011-0033

U.S. Department of Health & Human Services, NIH, National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. 179.

von Grueniger, V., Fraser, H., Fusco, N., DeBernardo, R., Eldermire, E., Eaton, S., & Waggoner, S. (2010). A Double-Blind, Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Pegylated Liposomal Doxorubicin-Related Hand-Foot Syndrome in Gynecologic Oncology Patinets. Cancer , 116 (20), 4735-4743. DOI: 10.1002/cncr.25262

Wolf, S., Qin, R., Menon, S., Rowland, K., Thomas, S., Delaune, R., Christian, D., Pajon, E., Satele, D., Berenberg, J., & Loprinzi, C. (2010). Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5. Journal of Clinical Oncology , 28 (38), 5182-5187. DOI: 10.1200/JCO.2010.31.1431

Yen-Revollo, J. G. (2008). Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused By Fluoropyrimidines? Clinical Cancer Research , 14, 8-13. doi:10.1158/1078-0432.CCR-07-1225

Zhang, R. W. (2012). Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase II trial. 23, 1348-1353. doi:10.1093/annonc/mdr400

Appendix 1: Reported incidence of hand-foot syndrome associated with various therapies.(Degen et al., 2010)



Incidence PPE

Incidence of severe PPE (grade 3)


2 x 400 mg/day

34% - 48%

Grade 2/3: 17-30%

Grade 3: 9%

Sorafenib + Bevacizumab

2 x 200-400 mg/day


Grade 2/3: 57%


50 mg/day




37.5-50 mg/day






100 mg/m2 every 3 weeks




30 mg/m2 every 14 days


Pegylated liposomal doxorubicin

40-50 mg/m2 every 3-4 weeks


Grade 2/3: 20%

Pegylated liposomal doxorubicin

20 mg/m2 every 2-3 weeks




2 X 1250 mg/day












+ DPD inhibitor (eniluracil)




1000 mg/m2



100 mg/m2


Docetaxel + capecitabine



Doxorubicin + continuous 5-FU

20-30 mg/m2/2 weeks

1400 mg/m2/week



Palabras clave

Haga clic en cualquiera de estos términos para más artículos relacionados

Frequently Asked Questions

Manténgase informado con las últimas informaciones de OncoLink!   Suscribirse a OncoLink eNews
Ver nuestros archivos de boletines